Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Intensive Accelerated iTBS for the Treatment-Resistant Depression

NCT: NCT06166082 · COMPLETED

NCT IDNCT06166082
StatusCOMPLETED
Start Date2023-12-22
Completion2025-04-21

Brief Summary

This study is a multicenter, randomized, double-blind, and sham-controlled trial using most intensive aiTBS protocol (10 sessions daily over 5 consecutive days at triple the standard per-session dose) to investigate the antidepressant efficacy for treatment-resistant depression (TRD). Patients will be recruited and randomly assigned (1:1 ratio) to receive active or sham groups from 5 hospitals in China. The interventions will last for 5 days and both groups will be followed up for 8 weeks on the same time schedules. During the intervention and at least the first 4 weeks of post-treatment, participants will keep a stable antidepressant regimen. The individualized target in the left dorsolateral prefrontal cortex (DLPFC) will be generated from 30 minutes of resting-state functional MRI collected at baseline.

Frequently Asked Questions

What is Intensive Accelerated iTBS for the Treatment-Resistant Depression?

Intensive Accelerated iTBS for the Treatment-Resistant Depression is a clinical trial registered under NCT06166082. Current status: COMPLETED.

What is the status of NCT06166082?

The current status of NCT06166082 (Intensive Accelerated iTBS for the Treatment-Resistant Depression) is: COMPLETED.

When did Intensive Accelerated iTBS for the Treatment-Resistant Depression start?

Intensive Accelerated iTBS for the Treatment-Resistant Depression started on 2023-12-22.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.